Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Ticker
$INCY
Sector
Primary listing
Employees
2,844
Headquarters
Website
Incyte Metrics
BasicAdvanced
$20bn
14.02
$7.06
0.80
-
Price and volume
Market cap
$20bn
Beta
0.8
52-week high
$112.29
52-week low
$66.74
Average daily volume
1.7m
Financial strength
Current ratio
3.715
Quick ratio
3.402
Long term debt to equity
0.602
Total debt to equity
0.701
Interest coverage (TTM)
622.34%
Profitability
EBITDA (TTM)
1,549.123
Gross margin (TTM)
52.76%
Net profit margin (TTM)
26.71%
Operating margin (TTM)
27.13%
Effective tax rate (TTM)
19.28%
Revenue per employee (TTM)
$1,890,000
Management effectiveness
Return on assets (TTM)
13.89%
Return on equity (TTM)
30.82%
Valuation
Price to earnings (TTM)
14.023
Price to revenue (TTM)
3.63
Price to book
3.52
Price to tangible book (TTM)
3.68
Price to free cash flow (TTM)
13.698
Free cash flow yield (TTM)
7.30%
Free cash flow per share (TTM)
7.227
Growth
Revenue change (TTM)
21.48%
Earnings per share change (TTM)
7,175.41%
3-year revenue growth (CAGR)
15.60%
10-year revenue growth (CAGR)
20.11%
3-year earnings per share growth (CAGR)
69.59%
10-year earnings per share growth (CAGR)
39.79%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Business Wire·4 days ago
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Business Wire·5 days ago
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Business Wire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs